Tadalafil for Benign Prostatic Hyperplasia
Tadalafil 5 mg once daily is FDA-approved and indicated for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH) in adult men, taken at approximately the same time every day. 1
Specific FDA-Approved Indications
The FDA label clearly delineates three distinct indications for tadalafil:
- BPH alone: Tadalafil 5 mg once daily for treatment of lower urinary tract symptoms (LUTS) secondary to BPH 1
- BPH with concurrent erectile dysfunction (ED): Tadalafil 5 mg once daily for simultaneous treatment of both ED and BPH signs/symptoms 1
- Combination therapy: When initiating BPH treatment with both tadalafil and finasteride, tadalafil 5 mg once daily is recommended for up to 26 weeks, as the incremental benefit decreases from 4 to 26 weeks and is unknown beyond 26 weeks 1
Dosing Specifications
The only approved dose for BPH is 5 mg once daily - this is non-negotiable and differs from the as-needed dosing used for ED alone 1. The medication should be:
- Taken at approximately the same time each day
- Administered without regard to timing of sexual activity (when treating BPH)
- Taken without regard to food 1
Clinical Efficacy Evidence
The FDA approval was based on robust clinical trial data demonstrating significant improvements in International Prostate Symptom Score (IPSS). In the pivotal trials enrolling over 1,000 men with moderate to severe BPH symptoms:
- Mean IPSS improvement: -4.8 to -5.6 points from baseline versus -2.2 to -3.6 with placebo (p<0.004) 1
- Onset of action: Approximately 60% of responders achieved clinically meaningful improvement (≥3-point IPSS reduction) within 1 week, and over 70% within 4 weeks 2
- Sustained benefit: Improvements maintained through 12 months of continued therapy 1, 3
The mechanism involves PDE5 inhibition leading to smooth muscle relaxation in the prostate, bladder neck, and supporting vasculature, increased blood perfusion to the lower urinary tract, and modulation of bladder afferent nerve activity 4.
Special Populations Requiring Dose Adjustment
Renal Impairment
- CrCl 30-50 mL/min: Start with 2.5 mg once daily; may increase to 5 mg based on response 1
- CrCl <30 mL/min or hemodialysis: Tadalafil once daily is not recommended for BPH 1
Hepatic Impairment
- Mild to moderate (Child-Pugh A or B): Use with caution; not extensively studied 1
- Severe (Child-Pugh C): Contraindicated - do not use 1
Elderly (≥75 years)
The efficacy data in men ≥75 years showed less robust improvement compared to younger men, though the safety profile remained acceptable 5. This age group typically has more comorbidities and concomitant medications that may reduce efficacy. Consider this when setting expectations, though the medication remains an option if other factors are favorable.
Critical Safety Considerations
Absolute contraindication: Concomitant use with nitrates in any form is strictly prohibited due to potentially life-threatening hypotension 1.
Common adverse events include:
- Headache
- Dyspepsia
- Back pain
- Dizziness 6
Important caveat: Unlike alpha-blockers (which can cause orthostatic hypotension, dizziness, and retrograde ejaculation) and 5-alpha reductase inhibitors (which can cause sexual dysfunction), tadalafil actually improves erectile function when present, making it particularly advantageous for men with concurrent ED and BPH 7.
Clinical Context from Guidelines
While the 2023 EAU guidelines 8 extensively discuss alpha-blockers and 5-alpha reductase inhibitors as primary BPH therapies, tadalafil represents an FDA-approved alternative that is particularly suited for men with both LUTS/BPH and ED. The drug label evidence takes precedence here, establishing tadalafil's legitimate role in BPH management beyond just ED treatment.